Overcoming Disease Recurrence and Treatment Resistance in HER2-Positive Metastatic Tumors – Tweetorial #4 Evaluation (ID: i807-9) Question Title * 1. How frequently do you now plan to employ emerging novel therapies and clinical trial enrollment for your patients? Very frequently Somewhat frequently Somewhat infrequently Very infrequently Question Title * 2. How many years have you been in practice? >21 11-20 1-10 <1 Question Title * 3. How many patients with solid tumors do you manage per week? 1 to 10 11 to 25 26 to 50 I am not directly involved in patient care Question Title * 4. Please select the option that best describes your practice setting. Academic medical center Community medical center VA, DOD, or other government Managed care Research Pharmaceutical industry Question Title * 5. After participating in this activity, how confident are you in the management of patients with solid tumors in your practice? Very confident Confident Neutral Little confidence No confidence Question Title * 6. How committed are you to making changes in your practice based on your participation in this activity? Very committed Committed Neutral Not committed I do not plan to make changes If not committed or do not plan to make changes, please indicate reason Question Title * 7. Which of the following best describes the impact of this activity on your performance? I gained new strategies/skills/information I can apply to my area of practice I need more information before I can change my practice My practice is already consistent with the information presented This activity will not change my practice Question Title * 8. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply. Have a better understanding of emerging HER2-targeted therapies Have an increased knowledge of clinical trial results Carefully select patients for treatment with HER2-targeted therapies Question Title * 9. What barriers do you see to making changes in your practice? Please select all that apply. Lack of knowledge regarding evidence-based strategies Lack of convincing evidence to warrant change Lack of time/resources to consider change Insurance, reimbursement or legal issues Conflicting guidelines or evidence Patient compliance and/or patient resource barriers Other (please specify) Question Title * 10. Please rate your level of agreement by checking the appropriate rating.5 = Strongly agree, 4 = Agree, 3 = Neutral, 2 = Disagree, 1 = Strongly disagree After participating in today’s activity, I am now better able to: Strongly agree Agree Neutral Disagree Strongly disagree ELUCIDATE the mechanisms of action and clinical trial findings of recently approved and emerging HER2/HER3-targeted drugs for multiple tumor types ELUCIDATE the mechanisms of action and clinical trial findings of recently approved and emerging HER2/HER3-targeted drugs for multiple tumor types Strongly agree ELUCIDATE the mechanisms of action and clinical trial findings of recently approved and emerging HER2/HER3-targeted drugs for multiple tumor types Agree ELUCIDATE the mechanisms of action and clinical trial findings of recently approved and emerging HER2/HER3-targeted drugs for multiple tumor types Neutral ELUCIDATE the mechanisms of action and clinical trial findings of recently approved and emerging HER2/HER3-targeted drugs for multiple tumor types Disagree ELUCIDATE the mechanisms of action and clinical trial findings of recently approved and emerging HER2/HER3-targeted drugs for multiple tumor types Strongly disagree Question Title * 11. Please rate your level of agreement by checking the appropriate rating. Strongly agree Agree Neutral Disagree Strongly disagree Faculty for this activity were effective Faculty for this activity were effective Strongly agree Faculty for this activity were effective Agree Faculty for this activity were effective Neutral Faculty for this activity were effective Disagree Faculty for this activity were effective Strongly disagree Content was scientifically rigorous and evidence based Content was scientifically rigorous and evidence based Strongly agree Content was scientifically rigorous and evidence based Agree Content was scientifically rigorous and evidence based Neutral Content was scientifically rigorous and evidence based Disagree Content was scientifically rigorous and evidence based Strongly disagree Avoided commercial bias or influence Avoided commercial bias or influence Strongly agree Avoided commercial bias or influence Agree Avoided commercial bias or influence Neutral Avoided commercial bias or influence Disagree Avoided commercial bias or influence Strongly disagree Question Title * 12. Please rate your level of agreement by checking the appropriate rating.The content presented: Strongly agree Agree Neutral Disagree Strongly disagree Enhanced my current knowledge base Enhanced my current knowledge base Strongly agree Enhanced my current knowledge base Agree Enhanced my current knowledge base Neutral Enhanced my current knowledge base Disagree Enhanced my current knowledge base Strongly disagree Addressed my most pressing questions Addressed my most pressing questions Strongly agree Addressed my most pressing questions Agree Addressed my most pressing questions Neutral Addressed my most pressing questions Disagree Addressed my most pressing questions Strongly disagree Promoted improvements or quality in health care Promoted improvements or quality in health care Strongly agree Promoted improvements or quality in health care Agree Promoted improvements or quality in health care Neutral Promoted improvements or quality in health care Disagree Promoted improvements or quality in health care Strongly disagree Was scientifically rigorous and evidence based Was scientifically rigorous and evidence based Strongly agree Was scientifically rigorous and evidence based Agree Was scientifically rigorous and evidence based Neutral Was scientifically rigorous and evidence based Disagree Was scientifically rigorous and evidence based Strongly disagree Avoided commercial bias or influence Avoided commercial bias or influence Strongly agree Avoided commercial bias or influence Agree Avoided commercial bias or influence Neutral Avoided commercial bias or influence Disagree Avoided commercial bias or influence Strongly disagree Question Title * 13. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice? Question Title * 14. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for solid tumors: Question Title * 15. If you indicated that you perceived commercial bias or influence, please describe: Done